Journals / Türk Üroloji Dergisi/Turkish Journal of Urology / 2002 / Cilt: 28 - Sayı: 1

Dehidroepiandrostenedion sulphate (DHEA-S) levels in erectile dysfunction patients

Erektil disfonksiyonlu hastalarda dehidroepiandrosteron sülfat (DHEA-S) düzeyleri

Pages
66–69
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

As a result, serum DHEA-S levels are lower in the erectile dysfunction patients without organic pathologies.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The aim of this study is to compare serum DHEA-S levels in the patients suffered from erectile dysfunction to healthy volunteers.
📊
Key Findings & Data:Fifty-nine patients with erectile dysfunction aged from 25 to 67 years (mean age 45.7+/-1.23) were enrolled in the study.
💡
Conclusion & Impact:As a result, serum DHEA-S levels are lower in the erectile dysfunction patients without organic pathologies.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Dehidroepiandrosteron sülfat · İmpotans · Tanı teknikleri

Abstract

The aim of this study is to compare serum DHEA-S levels in the patients suffered from erectile dysfunction to healthy volunteers. Fifty-nine patients with erectile dysfunction aged from 25 to 67 years (mean age 45.7+/-1.23) were enrolled in the study. All patients were evaluated detailed history, serum biochemical analysis and penile Doppler ultrasonography. After these investigations, patients were divided into two groups as organic and psychogenic erectile dysfunction. Fifteen healthy volunteers without any erectile problem were assigned to control group. Serum DHEA-S levels were also evaluated in these patients. Results were analyzed by using Kruskall Wallins Variant analysis and Mann Whitney U tests. Serum DHEA-S levels in organic and psychogenic erectile dysfunction patients and healthy volunteers were 263.4+/-6.7 (200-359), 205.6+/-10.03 (100-302), 292.19+/-10.6 (251-354) $\mu$g/dl, respectively. There was a significantly difference between the groups (p=0.000, p<0.05). As a result, serum DHEA-S levels are lower in the erectile dysfunction patients without organic pathologies.

Özet

Bu çalışmanın amacı erektil disfonksiyon yakınması ile başvuran erkeklerde serum dehidroepiandrostenedion sülfat (DHEA-S) düzeylerini sağlıklı kontrol grubu bireyler ile karşılaştırmaktır. 25-67 (ortalama yaş 45.7±1.23) arasında olan 59 hasta çalışmaya alındı. Tüm hastalar detaylı anamnez, serum biyokimya ve penil Doppler ultrasonografi ile değerlendirildi. Ayrıca, tüm hastalarda serum DHEA-S düzeyi çalışıldı. Bu tetkikler sonrası hastalar organik ve psikojenik olarak iki gruba ayrıldı. Çeşitli nedenlerle üroloji polikliniğine başvuran, ereksiyon yakınması olmayan aynı yaş grubunda 15 erkek hasta kontrol grubu olarak alındı. Bu hastalara da serum DHEA-S düzeyleri ölçüldü. Sonuçlar, Kruskall Wallins Varyans analizi ve Mann Whitney U test ile değerlendirildi. Organik ve psikojenik erektil disfonksiyonlu hastalar ile kontrol grubu bireylerin DHEA-S düzeyleri ortalamaları sırasıyla 263.4+/-6.7 (200-359), 205.6+/-10.03 (100-302), 292.19+/-10.6 (251-354) $\mu$g/dl olarak bulundu. DHEA-S düzeyleri gruplar arasında istatistiksel olarak farklı idi (p=0.000, p<0.05). Sonuç olarak organik bir neden bulunamayan erektil disfonksiyonlu hastalarda beklenen serum DHEA-S düzeyleri olasılıkla daha düşüktür.

🔖

Cite This Article

TEKDOĞAN, Ü. Y., BAŞAR, M. M., ÖZERGİN, O., ATAN, A. (2002). Dehidroepiandrostenedion sulphate (DHEA-S) levels in erectile dysfunction patients. Türk Üroloji Dergisi/Turkish Journal of Urology, Cilt: 28 - Sayı: 1, 66–69. https://ajindex.com/articles/328829

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (8)

  1. Orentreich N, Brind JL, Vogelman JH, Andreas R, Baldwin H: Long term longitudinal measurements of plasma Dehydroepiandrosterone sulfa-te in normal men. J Clin Endocrinol Metab 75; 1002-1004,1992
  2. Reiter WJ, Pycha A, Schatal G, Pokorny A, Gruber DM, Huber JC, Marberger M: De-hydroepiandrosteron in the treatment of erectile dysfunction: A prospective, double-blind, rando-mized, placebo-controlled study. Urology 53; 590-95, 1999
  3. Langcope C: Metabolism of dehydroepiandros-tenedion sulphate. J Endoc 150: 125-7, 1996
  4. Solente SB, Fioraventi M, Vognati G, Giustina A, Cravello L, Ferrari E: Dehydroepiandrostenedion sulphate enhances naturel killer cell cyto-toxicity in humans via locally generated immuno-reactive insulin like growth factor-I. J Clin Endoc Metab 8: 3260-7, 1999
  5. Reiter WJ, Schatzl G, Mark I, Zeiner A, Pycha A, Marberger M: Dehydroepiandrostenedion in the treatment of erectile dysfunction in patients with different organic etiologies. Urol Res 29: 278-81, 2001
  6. Reiter WJ, Pycha A, Schatazl G, Klinger HC, Mark I, Auterith A, Marberger M: Serum de-hydroepiandrostenedion sulphate concentrations in men with erectile dysfunction; Urology 55; 755-8, 2000
  7. Belanger A, Candas B, Dupont A, Cusan L, Diamond P, Gomez JL, Labrie F: Changes in serum concentration of conjugated and unconju-gated steroids in 4-to 80-year-old men. J Clin En-docrinol Metab 79: 1086-90, 1994
  8. Feldman HA, Goldstein I, Hatzichristou DG et al: Impotence and its medical and psychological correlates: Results of Massachusetts male aging study: J. Urol. 151: 54-61,1994 9- Labrie F, Belanger A, Cusan L, Gomez JL, Candas B: Marked decline in serum concentrations of adrenal C 19 sex steroids precursors and conjugated androgen metabolism during ageing. J Clin Endocrinol Metab 82: 2396-402, 1997.